Financial Data and Key Metrics Changes - The company recorded revenue of $2.1 million for Q2 2025, down from $5 million in Q2 2024, primarily due to short-term delays in completing certain multi-device enterprise health sales [8][9] - Gross profit for Q2 2025 was $800,000, representing a gross margin of approximately 40%, compared to a gross profit of $2.6 million and a gross margin of 53% for the same period in 2024 [9] - Operating expenses for Q2 2025 were $4.8 million, a 4% improvement from $5 million in Q2 2024 [10] - The net loss applicable to common stockholders for Q2 2025 was $2.7 million, or $1.24 per share, compared to a net loss of $2.4 million, or $1.99 per share, for the same period in 2024 [10] Business Line Data and Key Metrics Changes - The legacy enterprise health product, primarily the EksoNR device, experienced a decrease in revenue, while sales of the Ekso Indigo personal device increased [9][12] - Personal health product revenues grew by more than 50% in the first half of 2025, despite total revenues being down 38% compared to the same period in 2024 [15][23] Market Data and Key Metrics Changes - The company noted that a small percentage of U.S. customers were impacted by the loss of federal grants and economic uncertainties, which may delay purchases into later 2025 or early 2026 [12][13] - The company has developed a pipeline of over 45 Medicare beneficiaries qualified for the Ekso Indigo Personal, up more than 200% from the end of 2024 [19] Company Strategy and Development Direction - The company is focusing on a scalable go-to-market strategy for the Ekso Indigo Personal, supported by new distribution partners and marketing efforts [23] - A strategic initiative is underway to build a proprietary foundation model for human motion in physical rehabilitation, integrating new AI capabilities across the product portfolio [20][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that the second quarter revenue shortfall does not reflect the health of the current business or future prospects, citing expected closure of deferred sales [12][13] - The company is working to manage enterprise customer budgets and has engaged a third-party financial partner to assist in transitioning purchases from capital to operational budgets [42] Other Important Information - The company launched Ekso University, a virtual platform providing continuing education courses to physical therapists, aimed at increasing awareness and adoption of exoskeleton technology [14] - The company joined the NVIDIA Connect program to leverage AI and high-performance computing for product development [20][21] Q&A Session Summary Question: Can you quantify the deferred sales on the Enterprise Health side? - Management indicated that two multi-unit device sales fell out of Q2, with one being an international order and the other a North American IDN order expected to occur in Q3, totaling approximately $1.4 million [25][26] Question: When do you expect the Indigo Personal to overtake the Enterprise Health business? - Management believes that by 2025, the contribution from Personal Health will increase to about 25% of total revenue, with expectations to overtake Enterprise Health by 2027 [27][28] Question: How is the process of nailing down the patient profile progressing? - Management noted positive outcomes from recent ALJ hearings and emphasized the importance of ensuring the best claims possible for reimbursement [30] Question: Will Ekso University focus solely on exoskeletons? - Management stated that while initial courses will center on exoskeleton technology, future content will cover a broader range of neuro rehabilitation topics [32] Question: How are new collaborations aiding the commercialization of personal devices? - Management highlighted ongoing partnerships with industry leaders to navigate market access and build a scalable process for patient claims [37][40]

Core Viewpoint - Ekso Bionics Holdings, Inc. reported a significant decline in revenue for the second quarter of 2025, primarily due to lower sales of Enterprise Health devices, but anticipates recovery in the second half of the year driven by growth in Personal Health products [3][4]. Financial Performance - For Q2 2025, the company recorded revenue of $2.1 million, down from $5.0 million in Q2 2024, attributed mainly to decreased Enterprise Health device sales [4]. - Gross profit for Q2 2025 was $0.8 million, with a gross margin of approximately 40%, compared to $2.6 million and a gross margin of 53% in Q2 2024 [5]. - The net loss for Q2 2025 was $2.7 million, or $1.24 per share, compared to a net loss of $2.4 million, or $1.99 per share, in Q2 2024 [7][17]. Expenses - Sales and marketing expenses for Q2 2025 were $1.7 million, slightly down from $1.8 million in Q2 2024, mainly due to lower discretionary payroll [6]. - Research and development expenses decreased to $0.9 million in Q2 2025 from $1.1 million in Q2 2024, primarily due to a reduction in headcount [6]. - General and administrative expenses increased to $2.3 million in Q2 2025 from $2.0 million in Q2 2024, attributed to lower allocable costs to manufacturing [7]. Cash Position - As of June 30, 2025, the company had cash and restricted cash totaling $5.2 million, down from $6.5 million at the end of 2024 [8][15]. Strategic Developments - The company named Bionic Prosthetics & Orthotics Group as its first distributor for the Ekso Indego Personal device within the orthotics and prosthetics industry [10]. - Ekso Bionics was accepted into the NVIDIA Connect program, aiming to develop a proprietary foundation model for human motion and integrate AI capabilities across its product portfolio [10]. - The launch of eksoUniversity provides a library of continuing education courses for physical therapists and assistants working with patients with neurological conditions [10].

Core Insights - Ekso Bionics has successfully demonstrated a proof-of-concept for integrating AI capabilities into its exoskeleton devices, specifically targeting both medical and industrial applications [1][3] - The new AI voice agent, named "Ekso Voice Agent," is designed for intelligent control of the legacy EksoNR device and operates on NVIDIA Jetson Orin Nano hardware [2][3] - The company has a substantial data repository with approximately 350,000 patient sessions and over 15 million data points, which is increasing by an average of 60,000 patient steps daily, positioning it well to leverage AI in exoskeleton technology [3] Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility across various applications [5] - The company focuses on improving health and quality of life through advanced robotics, catering to individuals with paralysis and enhancing capabilities in industrial settings [5] - Ekso Bionics is headquartered in the San Francisco Bay Area and is publicly traded on the Nasdaq under the symbol "EKSO" [5] NVIDIA Connect Program - The company has been accepted into the NVIDIA Connect Program, which aims to accelerate product development and enhance cost efficiency for technology companies [4] - Members of this program receive specialized training, priority engineering support, and access to NVIDIA's advanced development kits and GPU platforms [4]

Core Insights - Ekso Bionics has successfully demonstrated a proof-of-concept for integrating AI capabilities into its exoskeleton devices, enhancing user interaction and control [1][3] - The new AI voice agent, named "Ekso Voice Agent," is designed for intelligent control of the EksoNR device and operates on NVIDIA Jetson Orin Nano hardware [2][3] - The company has a substantial data repository with approximately 350,000 patient sessions and over 15 million data points, which is growing by an average of 60,000 patient steps daily, positioning it well to leverage AI in exoskeleton technology [3] Company Overview - Ekso Bionics is a leader in developing exoskeleton solutions aimed at enhancing human strength, endurance, and mobility for both medical and industrial applications [5] - The company focuses on improving health and quality of life through advanced robotics, offering technologies that assist individuals with paralysis and enhance capabilities in various job sites [5] - Ekso Bionics is headquartered in the San Francisco Bay Area and is publicly traded on the Nasdaq under the symbol "EKSO" [5] NVIDIA Connect Program - The NVIDIA Connect Program is designed to accelerate product development for technology companies, providing specialized training, engineering support, and access to advanced development kits and GPU platforms [4] - Membership in this program is expected to help Ekso Bionics deliver next-generation solutions in AI and high-performance computing [4]

Financial Data and Key Metrics Changes - The company recorded revenue of $3.4 million in Q1 2025, down from $3.8 million in Q1 2024, attributed to capital budget impacts from certain inpatient rehabilitation facilities related to the EksoNR enterprise health product [7] - Gross profit for Q1 was $1.8 million, representing a gross margin of approximately 54%, compared to a gross profit of $2 million and a gross margin of 52% for the same period in 2024 [8] - Operating expenses for Q1 2025 were $5.3 million, essentially unchanged from $5.2 million in Q1 2024 [9] - Net loss applicable to common stockholders for Q1 2025 was $2.9 million or $0.12 per share, compared to a net loss of $3.4 million or $0.20 per share in Q1 2024 [9] - Cash and restricted cash as of March 31, 2025, was $8.1 million, up from $6.5 million at the end of 2024 [10] Business Line Data and Key Metrics Changes - The enterprise health segment saw a reduction in revenue, while the Ekso Indigo Personal experienced good growth, indicating a shift in revenue contributions [11] - The company has developed a pipeline of over 35 Medicare beneficiaries qualified for the Ekso Indigo Personal in 2025, a 37% increase from the previous quarter [13] Market Data and Key Metrics Changes - The company noted softness in the legacy enterprise business due to capital budget impacts from customers reacting to macroeconomic uncertainties [11] - The regulatory change by CMS in Q2 2024 created significant opportunities for the Ekso Indigo Personal, removing barriers for Medicare enrollees with spinal cord injuries [11] Company Strategy and Development Direction - The company is focusing on building a scalable go-to-market strategy for the Ekso Indigo Personal, leveraging partnerships with Priya Healthcare and Bionic P and O to enhance market access [12][14] - The majority of revenue in 2025 is expected to still come from enterprise health, but significant contributions from personal health products are anticipated as the year progresses [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growing pipeline of Medicare beneficiaries and the potential for increased contributions from personal health products throughout 2025 [17] - There are concerns about the impact of economic uncertainties on capital budgets, particularly for inpatient rehabilitation facilities, which could affect future sales [27] Other Important Information - The company has engaged with National Seating and Mobility as an exclusive distributor for the Ekso Indigo Personal within the U.S. Complex Rehabilitation Technology industry [14] - The partnerships with distribution networks are expected to enhance the company's ability to process claims and improve operational efficiency [39][41] Q&A Session Summary Question: How should investors think about where the patients will fall this year in terms of the Indigo Personal? - Management expects that enterprise products will represent 75% to 80% of the business, with solid contributions from personal products growing quarter over quarter [20] Question: Any more color on how things are going with claims submissions? - Management believes they have a strong understanding of what constitutes a solid claim and that current submissions have a high probability of success [24] Question: What is the outlook on capital budgeting from IDNs? - Management noted that while there was softness in Q1, they expect solid contributions from IDNs in 2025 as many renewals are on track [26] Question: Is the current gross margin a new baseline? - Management believes that with continued operational improvements, gross margins can be maintained or improved as revenues expand [29]